Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 4/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10192542 | 0.82 | MEN1 (0.53) | KMT2AMEN1POLB | |
| SCHEMBL3673898 | 0.75 | KCNK3 (0.61) | TOP1KMT2AMEN1PKMPOLB | |
| SCHEMBL21146096 | 0.74 | NPC1 (0.54) | KMT2AMEN1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL179004 | 0.73 | TOP1 (0.83) | TOP1KMT2AMEN1PKMPOLB | |
| SCHEMBL25872216 | 0.73 | KCNK3 (0.62) | KMT2AMEN1TDP1NPC1RAB9A | |
| SCHEMBL6469977 | 0.72 | NPC1 (0.71) | KMT2AMEN1HTTNPC1RAB9A | |
| SCHEMBL27835354 | 0.71 | NQO2 (0.59) | TOP1KMT2AMEN1LMNARECQL | |
| SCHEMBL6530432 | 0.71 | KCNK3 (0.76) | KMT2AMEN1POLBALDH1A1NPC1 | |
| SCHEMBL30799014 | 0.71 | KCNK3 (0.76) | KMT2AMEN1POLBALDH1A1NPC1 | |
| SCHEMBL6848357 | 0.71 | ALDH1A1 (0.71) | KMT2AMEN1PKMHTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120108592-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF SALICYLANILIDES FOR TREATMENT OF HEPATITIS VIRUSES | ROMARK LABORATORIES, L.C. | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108592-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF SALICYLANILIDES FOR TREATMENT OF HEPATITIS VIRUSES | PYGL, GYS2, GLS2 | TOP1 2562/4885KMT2A 3654/4885MEN1 4455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.